Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951015 · ClinicalTrials.gov registry record · Phase 2
A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
NCT00951015 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 208 participants.
The verdict
NCT00951015, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
Study Summary
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
Interventions
- DRUG efavirenz
- DRUG GSK1349572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2009-07-30 |
| Est. Completion | 2016-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951015
The ClinicalTrials.gov registry entry for NCT00951015 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which efavirenz is the first listed.
NCT00951015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951015 about?
NCT00951015 is a clinical study titled "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects". This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.
What is the current status of trial NCT00951015?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2009-07-30. Estimated completion is 2016-12-22.
What interventions are being tested in trial NCT00951015?
The interventions under investigation include: efavirenz (DRUG), GSK1349572 (DRUG).
Who is sponsoring clinical trial NCT00951015?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.